Virtu Financial’s Soleno Therapeutics SLNO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-8,244
| Closed | -$276K | – | 2190 |
|
|
2026
Q1 | $276K | Sell |
8,244
-14,634
| -64% | -$574K | 0.01% | 854 |
|
|
2025
Q4 | $1.06M | Buy |
+22,878
| New | +$1.25M | 0.04% | 339 |
|
|
2025
Q2 | – | Sell |
-14,396
| Closed | -$1.03M | – | 1997 |
|
|
2025
Q1 | $1.03M | Buy |
+14,396
| New | +$701K | 0.06% | 273 |
|
|
2024
Q4 | – | Sell |
-9,706
| Closed | -$490K | – | 2015 |
|
|
2024
Q3 | $490K | Buy |
+9,706
| New | +$465K | 0.03% | 459 |
|
|
2022
Q3 | – | Sell |
-4,505
| Closed | -$12K | – | 2195 |
|
|
2022
Q2 | $12K | Buy |
+4,505
| New | +$12.5K | ﹤0.01% | 1409 |
|
|
2022
Q1 | – | Sell |
-1,575
| Closed | -$10K | – | 1988 |
|
|
2021
Q4 | $10K | Buy |
+1,575
| New | +$16.5K | ﹤0.01% | 1578 |
|
|
2021
Q1 | – | Sell |
-2,907
| Closed | -$84K | – | 1988 |
|
|
2020
Q4 | $84K | Sell |
2,907
-1,119
| -28% | -$32.3K | 0.01% | 1106 |
|
|
2020
Q3 | $152K | Sell |
4,026
-568
| -12% | -$16.6K | 0.03% | 647 |
|
|
2020
Q2 | $153K | Buy |
+4,594
| New | +$199K | 0.02% | 781 |
|
|
2019
Q2 | – | Sell |
-2,339
| Closed | -$72K | – | 1821 |
|
|
2019
Q1 | $72K | Buy |
+2,339
| New | +$62.2K | ﹤0.01% | 1167 |
|
|
2018
Q3 | – | Sell |
-1,210
| Closed | -$42K | – | 2120 |
|
|
2018
Q2 | $42K | Buy |
+1,210
| New | +$35.5K | ﹤0.01% | 1787 |
|
|
2017
Q4 | – | Sell |
-706
| Closed | -$28K | – | 2954 |
|
|
2017
Q3 | $28K | Buy |
+706
| New | +$27.8K | ﹤0.01% | 2297 |
|
Virtu Financial's SLNO Position: Q2 2026 in Review
Virtu Financial sold out of Soleno Therapeutics (SLNO) in Q2 2026, closing a stake of 8,244 shares — an estimated $276K sold.
Virtu Financial first reported a position in SLNO in Q3 2017 and held it in 12 quarters. The position peaked at $1.06M in Q4 2025. 0 funds tracked by Wall St. Rank hold SLNO as of Q2 2026.
- Virtu Financial reported no remaining Soleno Therapeutics position as of Q2 2026 after selling out during the quarter.
- Virtu Financial sold 8,244 Soleno Therapeutics shares in Q2 2026, an estimated $276K.
- Virtu Financial first reported a position in Soleno Therapeutics in Q3 2017 and held it in 12 quarters.
- Virtu Financial's Soleno Therapeutics position peaked at $1.06M in Q4 2025.
- 0 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q2 2026.
Based on Virtu Financial's 13F filing for Q2 2026, filed 13 Aug 2026.